ADC Therapeutics S.A. (ADCT) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $1.51 (+1.34%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 3, 2025 | Gregory Renza | RBC Capital | $5.00 | +231.1% |
| Nov 12, 2025 | Michael Schmidt | Guggenheim | $10.00 | +562.3% |
| May 7, 2024 | Robert Burns | H.C. Wainwright | $8.00 | +429.8% |
| Mar 13, 2024 | Kelly Shi | Jefferies | $13.00 | +760.9% |
| Sep 9, 2022 | Matthew Harrison | Morgan Stanley | $11.00 | +628.5% |
Top Analysts Covering ADCT
ADCT vs Sector & Market
| Metric | ADCT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.40 | 2.25 | 2.41 |
| Analyst Count | 5 | 8 | 19 |
| Target Upside | +131.8% | +153002.0% | +21.5% |
| P/E Ratio | -3.97 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20M | $21M | $23M | 2 |
| 2027-12-31 | $117M | $133M | $147M | 5 |
| 2028-12-31 | $255M | $278M | $300M | 5 |
| 2029-12-31 | $371M | $406M | $437M | 2 |
| 2030-12-31 | $419M | $458M | $493M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.22 | $-0.20 | $-0.19 | 1 |
| 2027-12-31 | $-0.85 | $-0.64 | $-0.26 | 5 |
| 2028-12-31 | $-0.65 | $0.04 | $0.62 | 4 |
| 2029-12-31 | $0.54 | $0.60 | $0.66 | 2 |
| 2030-12-31 | $0.73 | $0.82 | $0.90 | 2 |
Frequently Asked Questions
What is the analyst consensus for ADCT?
The consensus among 5 analysts covering ADC Therapeutics S.A. (ADCT) is Buy with an average price target of $3.50.
What is the highest price target for ADCT?
The highest price target for ADCT is $13.00, set by Kelly Shi at Jefferies on 2024-03-13.
What is the lowest price target for ADCT?
The lowest price target for ADCT is $5.00, set by Gregory Renza at RBC Capital on 2025-12-03.
How many analysts cover ADCT?
5 analysts have issued ratings for ADC Therapeutics S.A. in the past 12 months.
Is ADCT a buy or sell right now?
Based on 5 analyst ratings, ADCT has a consensus rating of Buy (2.40/5) with a +131.8% upside to the consensus target of $3.50.
What are the earnings estimates for ADCT?
Analysts estimate ADCT will report EPS of $-0.20 for the period ending 2026-12-31, with revenue estimated at $21M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.